Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
Method
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
Items 101–200 of 963
Gordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
“In vitro autoradiography of PET amyloid tracers reveal a high affinity to plaques that are immunoreactive to amyloid-b42 or amyloid-b40 (Ikonomovic et al., 2008).”
BackgroundInfluentialMcBride, J. C., Zhao, X., Munro, N. B., Smith, C. D., Jicha, G. A., Hively, L., Broster, L. S., Schmitt, F. A., Kryscio, R. J., & Jiang, Y. (2014) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2014.01.019 · Cited by 176
“The regional variations in PiB binding in vivo are strikingly similar to the deposits of amyloid beta and tau neurofibrillary tangle distributions post-mortem [12].”
BackgroundCSF biomarkers cutoffs: The importance of coincident neuropathological diseases
Toledo, J. B., Brettschneider, J., Grossman, M., Arnold, S. E., Hu, W. T., Xie, S. X., Lee, V. M.-Y., Shaw, L. M., & Trojanowski, J. Q. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0983-7 · Cited by 182
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI
Toledo, J. B., Vanderstichele, H., Figurski, M., Aisen, P. S., Petersen, R. C., Weiner, M. W., Jack, C. R., Jagust, W., Decarli, C., Toga, A. W., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0861-8 · Cited by 177
“These findings, coupled with other data, led to the amyloid cascade hypothesis and thus to the development of biomarkers to measure A b pathology including A b imaging and measurements of A b peptides in cerebrospinal fluid (CSF) and plasma [22, 49].”
Development of Positron Emission Tomography β-Amyloid Plaque Imaging Agents
Mathis, C. A., Mason, N. S., Lopresti, B. J., & Klunk, W. E. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.07.001 · Cited by 175
Self-citationDementia of the Alzheimer Type
Jalbert, J. J., Daiello, L. A., & Lapane, K. L. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn008 · Cited by 174
In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain
Sepulcre, J., Schultz, A. P., Sabuncu, M., Gomez-Isla, T., Chhatwal, J., Becker, A., Sperling, R., & Johnson, K. A. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0639-16.2016 · Cited by 172
Multimodality imaging characteristics of dementia with Lewy bodies
Kantarci, K., Lowe, V. J., Boeve, B. F., Weigand, S. D., Senjem, M. L., Przybelski, S. A., Dickson, D. W., Parisi, J. E., Knopman, D. S., Smith, G. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.024 · Cited by 174
“The distinction between neuritic and diffuse plaques however is not possible with PiB PET, because PiB labels both neuritic and diffuse plaques, although labeling of diffuse/amorphous plaques is less prominent than compact/cored plaques (Ikonomovic et al., 2008; Lockhart et al., 2007, Sojkova et al., 2011).”
BackgroundENIGMA and the individual: Predicting factors that affect the brain in 35 countries worldwide
Thompson, P. M., Andreassen, O. A., Arias-Vasquez, A., Bearden, C. E., Boedhoe, P. S., Brouwer, R. M., Buckner, R. L., Buitelaar, J. K., Bulayeva, K. B., Cannon, D. M., et al. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2015.11.057 · Cited by 181
Villemagne, V. L., Ataka, S., Mizuno, T., Brooks, W. S., Wada, Y., Kondo, M., Jones, G., Watanabe, Y., Mulligan, R., Nakagawa, M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.285 · Cited by 174
Brain amyloid and cognition in Lewy body diseases
Gomperts, S. N., Locascio, J. J., Marquie, M., Santarlasci, A. L., Rentz, D. M., Maye, J., Johnson, K. A., & Growdon, J. H. (2012) · Movement Disorders · doi:10.1002/mds.25048 · Cited by 168
“PiB labels neuritic plaques as well as some diffuse plaques, and PiB retention in cases of DLB and PDD appears to relate to diffuse plaque burden.(43,56,57,59) The extent to which diffuse plaques contribute to cognitive impairment in Lewy body diseases remains to be determined.”
BackgroundSynaptic Change in the Posterior Cingulate Gyrus in the Progression of Alzheimer's Disease
Scheff, S. W., Price, D. A., Ansari, M. A., Roberts, K. N., Schmitt, F. A., Ikonomovic, M. D., & Mufson, E. J. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-141518 · Cited by 165
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia
Burack, M. A., Hartlein, J., Flores, H. P., Taylor-Reinwald, L., Perlmutter, J. S., & Cairns, N. J. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c7da8e · Cited by 164
Characterizing Alzheimer's disease using a hypometabolic convergence index
Chen, K., Ayutyanont, N., Langbaum, J. B. S., Fleisher, A. S., Reschke, C., Lee, W., Liu, X., Bandy, D., Alexander, G. E., Thompson, P. M., et al. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.049 · Cited by 162
“The best established biomarkers of AD pathology are fibrillar amyloid-β (Aβ) PETmeasurements using Pittsburgh Compound B (PiB) (Ikonomovic et al., 2008; Klunk et al., 2004) or other recently developed radioligand (Wong et al., 2010) and cerebrospinal fluid (CSF) amyloidbeta1–42 (Aβ1–42) levels…”
MethodNeuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection
Risacher, S. L., & Saykin, A. J. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185535 · Cited by 151
“…anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript primary signal measured in studies with [11C]PiB is the result of specific binding to amyloid plaques, with a high correlation between the anatomical distribution of [11C]PiB binding and post-mortem amyloid (Ikonomovic et al. 2008).”
BackgroundRelationship of Cerebrospinal Fluid Markers to11C-PiB and18F-FDDNP Binding
Tolboom, N., van der Flier, W. M., Yaqub, M., Boellaard, R., Verwey, N. A., Blankenstein, M. A., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.064360 · Cited by 160
“11C-PiB was designed to measure the amount of fibrillar Ab deposits (4,5), which has been confirmed by a postmortem study in AD (6).”
BackgroundReiman, E. M., Langbaum, J. B., & Tariot, P. N. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.91 · Cited by 157
Thal, D. R., Beach, T. G., Zanette, M., Heurling, K., Chakrabarty, A., Ismail, A., Smith, A. P. L., & Buckley, C. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.018 · Cited by 159
“In vitro-labeling experiments with the [11C]-labeled amyloid tracer Pittsburg compound B (PIB) disclose plaques on histopathologic slides [7].”
ResultInfluentialMormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L., & Jagust, W. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.07.098 · Cited by 158
“Comparison of PIB values to Aβ detected in brain tissue (via postmortem examination and brain biopsy) has shown that elevated PIB uptake is present in cases with high quantities of neuritic Aβ plaques, however the concordance between these measurements is inconclusive in subjects with evidence of low Aβ burden (Bacska…”
Amyloid pathology and axonal injury after brain trauma
Scott, G., Ramlackhansingh, A. F., Edison, P., Hellyer, P., Cole, J., Veronese, M., Leech, R., Greenwood, R. J., Turkheimer, F. E., Gentleman, S. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002413 · Cited by 148
Wolk, D. A. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.153 · Cited by 156
“As with (11)C-PiB, binding is expected to be more prominent to neuritic than diffuse plaques.(16) The current results are consistent with the still relatively limited, but accruing, histopathological data for (11)CPiB PET imaging.”
The diagnostic value of FDG and amyloid PET in Alzheimer’s disease—A systematic review
Rice, L., & Bisdas, S. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.07.014 · Cited by 168
PET imaging of brain amyloid in dementia: a review
Quigley, H., Colloby, S. J., & O'Brien, J. T. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2640 · Cited by 150
“Both studies, one in AD the other in PDD demonstrated high selectivity of PIB for fibrillar Ab deposits (Ikonomovic et al., 2008; Burack et al., 2010).”
BackgroundCognition, glucose metabolism and amyloid burden in Alzheimer's disease
Furst, A. J., Rabinovici, G. D., Rostomian, A. H., Steed, T., Alkalay, A., Racine, C., Miller, B. L., & Jagust, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.011 · Cited by 144
Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease
Leinonen, V., Koivisto, A. M., Savolainen, S., Rummukainen, J., Tamminen, J. N., Tillgren, T., Vainikka, S., Pyykkö, O. T., Mölsä, J., Fraunberg, M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22100 · Cited by 150
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
Caroli, A., & Frisoni, G. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.024 · Cited by 148
Braak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 156
Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 160
Vlassenko, A. G., Mintun, M. A., Xiong, C., Sheline, Y. I., Goate, A. M., Benzinger, T. L. S., & Morris, J. C. (2011) · Annals of Neurology · doi:10.1002/ana.22608 · Cited by 144
“Nonfibrillar Ab deposits may not be detected by PiB.17,18”
BackgroundJanelidze, S., Pannee, J., Mikulskis, A., Chiao, P., Zetterberg, H., Blennow, K., & Hansson, O. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2814 · Cited by 147
Madsen, S. K., Ho, A. J., Hua, X., Saharan, P. S., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.002 · Cited by 143
Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand
Juréus, A., Swahn, B., Sandell, J., Jeppsson, F., Johnson, A. E., Johnström, P., Neelissen, J. A. M., Sunnemark, D., Farde, L., & Svensson, S. P. S. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06812.x · Cited by 141
“[11C]PIB has been evaluated in over 40 different centers and in 3000 participants around the worlds, including postmortem analysis of AD patients (Ikonomovic et al. 2008; Klunk and Mathis 2008).”
BackgroundKadir, A., Marutle, A., Gonzalez, D., Schöll, M., Almkvist, O., Mousavi, M., Mustafiz, T., Darreh-Shori, T., Nennesmo, I., & Nordberg, A. (2011) · Brain · doi:10.1093/brain/awq349 · Cited by 140
Da, X., Toledo, J. B., Zee, J., Wolk, D. A., Xie, S. X., Ou, Y., Shacklett, A., Parmpi, P., Shaw, L., Trojanowski, J. Q., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.11.010 · Cited by 135
“Aβ deposition can be measured using PET tracers (Clark et al., 2012a; Ikonomovic et al., 2008) which correlate with decrease in Aβ1–42 in CSF (Fagan et al., 2009; Toledo et al., 2011).”
Background3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
Apostolova, L. G., Hwang, K. S., Andrawis, J. P., Green, A. E., Babakchanian, S., Morra, J. H., Cummings, J. L., Toga, A. W., Trojanowski, J. Q., Shaw, L. M., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.003 · Cited by 137
Self-citationAshton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Brain imaging in the study of Alzheimer's disease
Reiman, E. M., & Jagust, W. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.075 · Cited by 130
“…between PET measurements of fibrillar Aβ at the end of life and subsequent neuropathological measurements of fibrillar Aβ (Clark et al., 2011; Ikonomovic et al., 2008; Sojkova et al., 2011), and the first of these ligands (florbetapir F18) is now being considered for regulatory agency…”
BackgroundInitiative, F. T. A. D. N., Pascoal, T. A., Mathotaarachchi, S., Mohades, S., Benedet, A. L., Chung, C.-O., Shin, M., Wang, S., Beaudry, T., Kang, M. S., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.37 · Cited by 133
“The motivation to explore these effects using amyloid-PET in our study is derived from its close association with A β plaques load 37 , whereas CSF total tau and p-tau may provide additional information regarding neurodegeneration and neurofibrillary tangles load, respectively 38, 39 .”
Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia
Benussi, A., Di Lorenzo, F., Dell'Era, V., Cosseddu, M., Alberici, A., Caratozzolo, S., Cotelli, M. S., Micheli, A., Rozzini, L., Depari, A., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004232 · Cited by 133
Cerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 121
Choi, S. R., Schneider, J. A., Bennett, D. A., Beach, T. G., Bedell, B. J., Zehntner, S. P., Krautkramer, M. J., Kung, H. F., Skovronsky, D. M., Hefti, F., et al. (2012) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31821300bc · Cited by 129
Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue
Ni, R., Gillberg, P.-G., Bergfors, A., Marutle, A., & Nordberg, A. (2013) · Brain · doi:10.1093/brain/awt142 · Cited by 133
Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition
Kantarci, K., Lowe, V. J., Lesnick, T. G., Tosakulwong, N., Bailey, K. R., Fields, J. A., Shuster, L. T., Zuk, S. M., Senjem, M. L., Mielke, M. M., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160258 · Cited by 122
“PiB retention on PET imaging is a quantitative measure of A β deposition [26].”
Leuzy, A., Chiotis, K., Hasselbalch, S. G., Rinne, J. O., de Mendonça, A., Otto, M., Lleó, A., Castelo-Branco, M., Santana, I., Johansson, J., et al. (2016) · Brain · doi:10.1093/brain/aww160 · Cited by 131
“In addition, since PiB binds only weakly to amorphous amyloid-b plaques (Bacskai et al., 2007; Ikonomovic et al., 2008), PiB prove unable to detect variants of Alzheimer’s disease characterized by the predominance of diffuse (non-fibrillar) plaques (Cairns et al.”
BackgroundThal, D. R., Griffin, W. S. T., & Braak, H. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00411.x · Cited by 134
“Moreover, PIB is a thioflavin S analogue [136] and, in doing so, does not detect all diffuse A -deposits that are seen immunohistochemically [134].”
BackgroundImaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B
Handen, B. L., Cohen, A. D., Channamalappa, U., Bulova, P., Cannon, S. A., Cohen, W. I., Mathis, C. A., Price, J. C., & Klunk, W. E. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.09.229 · Cited by 131
“It has been shown that PiB stains compact/cored plaques more prominently than diffuse plaques [33].”
BackgroundSelf-citationSimilar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease
de Souza, L. C., Corlier, F., Habert, M.-O., Uspenskaya, O., Maroy, R., Lamari, F., Chupin, M., Lehéricy, S., Colliot, O., Hahn-Barma, V., et al. (2011) · Brain · doi:10.1093/brain/awr130 · Cited by 131
“11 C-labelled Pittsburgh compound-B ( C-PIB)-PET scanning measures the fibrillar amyloid-b deposition (Ikonomovic et al., 2008).”
BackgroundMethodMolecular and cellular pathophysiology of preclinical Alzheimer’s disease
Mufson, E. J., Ikonomovic, M. D., Counts, S. E., Perez, S. E., Malek-Ahmadi, M., Scheff, S. W., & Ginsberg, S. D. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.030 · Cited by 127
“It binds most prominently in NPs and vascular Aβ associated with cerebral amyloid angiopathy (CAA) [131], but does not bind to classic intracellular NFTs or other neuropathological elements [132].”
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies
Thompson, P. W., Ye, L., Morgenstern, J. L., Sue, L., Beach, T. G., Judd, D. J., Shipley, N. J., Libri, V., & Lockhart, A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05996.x · Cited by 137
“Finally, the labelling of the HIP formation section (HIP1) with PIB illustrates on a single section the differential sensitivity of the tracer for the hallmark AD pathologies and complements two recent studies, which in part, addressed this issue (Lockhart et al. 2007 and Ikonomovic et al. 2008).”
BackgroundResultInfluentialFarrell, M. E., Jiang, S., Schultz, A. P., Properzi, M. J., Price, J. C., Becker, J. A., Jacobs, H. I. L., Hanseeuw, B. J., Rentz, D. M., Villemagne, V. L., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011214 · Cited by 128
“Undoubtedly, toxic Aβ species exist, both soluble and insoluble isoforms, below these lower PET-detection thresholds, because PET tracers primarily have been found to bind to aggregated fibrillar Aβ.(40) The converging cutoffs based on Aβ-PET accumulation and cognitive decline may instead reflect the lowest point in t…”
BackgroundSelf-citationBrain effective connectivity during motor-imagery and execution following stroke and rehabilitation
Bajaj, S., Butler, A. J., Drake, D., & Dhamala, M. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2015.06.006 · Cited by 124
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
“measurement of amyloid plaque burden [38–44] and correlate well with post-mortem studies [44,45].”
BackgroundAmyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
Klunk, W. E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.006 · Cited by 129
“In addition, fibrillar Aβ can be found in varying degrees in plaques that have been loosely characterized as “diffuse”, and these diffuse plaques can be detected to some extent by amyloid imaging agents (Burack et al., 2010; Ikonomovic et al., 2008; Lockhart et al., 2007).”
BackgroundInfluentialSelf-citationCerebral microhemorrhage and brain β-amyloid in aging and Alzheimer disease
Yates, P. A., Sirisriro, R., Villemagne, V. L., Farquharson, S., Masters, C. L., Rowe, C. C., & For the AIBL Research Group (2011) · Neurology · doi:10.1212/wnl.0b013e318221ad36 · Cited by 130
Asymptomatic Alzheimers Disease: A Prodrome or a State of Resilience?
Driscoll, I., & Troncoso, J. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745348 · Cited by 130
Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review
Brown, B. M., Peiffer, J. J., & Rainey‐Smith, S. R. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.003 · Cited by 137
Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration
Jack, C. R., Wiste, H. J., Knopman, D. S., Vemuri, P., Mielke, M. M., Weigand, S. D., Senjem, M. L., Gunter, J. L., Lowe, V., Gregg, B. E., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000386 · Cited by 125
Follow-up of [ 11 C]PIB uptake and brain volume in patients with Alzheimer disease and controls
Scheinin, N. M., Aalto, S., Koikkalainen, J., Lötjönen, J., Karrasch, M., Kemppainen, N., Viitanen, M., Någren, K., Helin, S., Scheinin, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bacf1b · Cited by 128
Cruchaga, C., Kauwe, J. S. K., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., Shah, A. R., Abraham, R., Hollingworth, P., Harold, D., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001101 · Cited by 128
“Patients with AD show lower CSF Ab42 levels [19] that inversely correlate with the presence of fibrillar Ab in the brain (as measured by Pittsburgh Compound B (PET-PIB) retention) in demented individuals [14] and plaque counts in brain samples [20].”
BackgroundWolk, D. A., Zhang, Z., Boudhar, S., Clark, C. M., Pontecorvo, M. J., & Arnold, S. E. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302548 · Cited by 122
Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
Su, Y., Flores, S., Hornbeck, R. C., Speidel, B., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., Xiong, C., Morris, J. C., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.04.022 · Cited by 126
Self-citationHsiao, I., Huang, C., Hsieh, C., Hsu, W.-C., Wey, S., Yen, T., Kung, M., & Lin, K. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2051-2 · Cited by 133
“From autopsy studies AD is characterized by extracellular accumulation of amyloid plaques and intracellular neurofibrillary tangles [1, 2].”
BackgroundDistinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution
Rosenbloom, M. H., Alkalay, A., Agarwal, N., Baker, S. L., O'Neil, J. P., Janabi, M., Yen, I. V., Growdon, M., Jang, J., Madison, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821cccad · Cited by 121
Schmidt, M. E., Chiao, P., Klein, G., Matthews, D., Thurfjell, L., Cole, P. E., Margolin, R., Landau, S., Foster, N. L., Mason, N. S., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.09.004 · Cited by 125
“Preclinical profiling and autopsy studies have provided evidence that cerebral cortical retention of these tracers in vivo correlates with the burden of neuritic plaque load seen in the same brain regions postmortem [31,32,34] and at biopsy [65].”
BackgroundYao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E., & Brinton, R. D. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.005 · Cited by 123
“Studies conducted using brain tissue from autopsy-confirmed AD patients show that PiB binds only to fibrillar amyloid, particularly plaques that are immunoreactive for Ab40 or Ab42 (Ikonomovic et al., 2008).”
BackgroundInfluentialIaccarino, L., La Joie, R., Lesman-Segev, O. H., Lee, E., Hanna, L., Allen, I. E., Hillner, B. E., Siegel, B. A., Whitmer, R. A., Carrillo, M. C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3962 · Cited by 124
Alzheimer's disease: The next frontier—Special Report 2017
Karlawish, J., Jack, C. R., Rocca, W. A., Snyder, H. M., & Carrillo, M. C. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.02.006 · Cited by 113
“[38] Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC,”
BackgroundSmall-molecule PET Tracers for Imaging Proteinopathies
Mathis, C. A., Lopresti, B. J., Ikonomovic, M. D., & Klunk, W. E. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2017.06.003 · Cited by 123
“While NFTs are a common form of pathologic tau fibrils observed in AD brain, a diverse morphology of neurofibrillary pathology is observed, including neuropil threads in dendritic processes of neurons, straight filaments (SF), twisted ribbons (TR), and dystrophic neurites associated with classic Aβ plaques (138–140).”
BackgroundInfluentialSelf-citationMormino, E. C., & Papp, K. V. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179928 · Cited by 117
Zhang, S., Han, D., Tan, X., Feng, J., Guo, Y., & Ding, Y. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02845.x · Cited by 121
Harmonized diagnostic criteria for Alzheimer's disease: recommendations
Morris, J. C., Blennow, K., Froelich, L., Nordberg, A., Soininen, H., Waldemar, G., Wahlund, L. ‐., & Dubois, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12199 · Cited by 121
Maier, F. C., Wehrl, H. F., Schmid, A. M., Mannheim, J. G., Wiehr, S., Lerdkrai, C., Calaminus, C., Stahlschmidt, A., Ye, L., Burnet, M. W. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3734 · Cited by 132
Biomarkers in Alzheimer's disease drug development
Cummings, J. L. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 121
“The ligand used in Pittsburgh Compound B (PIB) PET labels fibrillar amyloid at postmortem [29,30].”
BackgroundAZD2184: a radioligand for sensitive detection of β‐amyloid deposits
Johnson, A. E., Jeppsson, F., Sandell, J., Wensbo, D., Neelissen, J. A. M., Juréus, A., Ström, P., Norman, H., Farde, L., & Svensson, S. P. S. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05861.x · Cited by 120
Mild to moderate Alzheimer dementia with insufficient neuropathological changes
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Blacker, D., Gómez‐Isla, T., Betensky, R. A., Growdon, J. H., Johnson, K. A., Frosch, M. P., Sperling, R. A., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24125 · Cited by 120
Bojar, M. (2009) · Cited by 120
Tau‐PET uptake: Regional variation in average SUVR and impact of amyloid deposition
Vemuri, P., Lowe, V. J., Knopman, D. S., Senjem, M. L., Kemp, B. J., Schwarz, C. G., Przybelski, S. A., Machulda, M. M., Petersen, R. C., & Jack, C. R. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.12.010 · Cited by 117
“PiBPET binds to insoluble (fibrillary) amyloid beta deposits and has been validated in autopsy studies [2,3].”
BackgroundZnO nanoflower based sensitive nano-biosensor for amyloid detection
Akhtar, N., Metkar, S. K., Girigoswami, A., & Girigoswami, K. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.04.118 · Cited by 120
Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease
Bulic, B., Pickhardt, M., & Mandelkow, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 114
Aging, Brain Disease, and Reserve: Implications for Delirium
Jones, R. N., Fong, T. G., Metzger, E., Tulebaev, S., Yang, F. M., Alsop, D. C., Marcantonio, E. R., Cupples, L. A., Gottlieb, G., & Inouye, S. K. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181b972e8 · Cited by 118
“In vivo measures of neuropathology in AD, such as amyloid imaging, have only recently been identified and are not widely available.(26) Autopsy studies have been used to identify the burden of disease in dementia.”
Amyloid PET Imaging in Lewy Body Disorders
Donaghy, P., Thomas, A. J., & O'Brien, J. T. (2015) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.03.001 · Cited by 117
In vivo characterization of the early states of the amyloid-beta network
Sepulcre, J., Sabuncu, M. R., Becker, A., Sperling, R., & Johnson, K. A. (2013) · Brain · doi:10.1093/brain/awt146 · Cited by 117
Regional brain hypometabolism is unrelated to regional amyloid plaque burden
Altmann, A., Ng, B., Landau, S. M., Jagust, W. J., & Greicius, M. D. (2015) · Brain · doi:10.1093/brain/awv278 · Cited by 115
“The correlation between plaque quantity and distribution as measured with PET and plaque quantity and distribution at autopsy is extraordinarily high (Ikonomovic et al. , 2008; Hatsuta et al. , 2015).”
Hatashita, S., Yamasaki, H., Suzuki, Y., Tanaka, K., Wakebe, D., & Hayakawa, H. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2564-y · Cited by 120
“Furthermore, the retention of PIBmeasured by PET imaging was directly related to Aβ-containing amyloid plaques in a postmortem study of the AD brain [7].”
Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements
McNamee, R. L., Yee, S.-H., Price, J. C., Klunk, W. E., Rosario, B., Weissfeld, L., Ziolko, S., Berginc, M., Lopresti, B., DeKosky, S., et al. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057612 · Cited by 111
“Use of the arterial DVR in the verification of simpler measurements is supported by our recent study that showed a strong correlation between PiB DVRCER values and region-matched postmortem correlates of amyloid deposition for a deceased AD patient who underwent PiB imaging before death (20).”
ResultSelf-citationSojkova, J., Driscoll, I., Iacono, D., Zhou, Y., Codispoti, K.-E., Kraut, M. A., Ferrucci, L., Pletnikova, O., Mathis, C. A., Klunk, W. E., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.357 · Cited by 113
“Potential factors that may affect the relation between in vivo imaging and CERAD-based assessment of NPs fall into 3 broad categories: (1) those related to CERAD’s semiquantitative assessment of Aβ, (2) those related to different forms of Aβ, and (3) other factors, such as the imaging–pathologic assessment interval.”
Self-citationAnalysis of Protein Aggregation in Neurodegenerative Disease
Pedersen, J. T., & Heegaard, N. H. H. (2013) · Analytical Chemistry · doi:10.1021/ac400023c · Cited by 121
Soares, H. D., Chen, Y., Sabbagh, M., Rohrer, A., Schrijvers, E., & Breteler, M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05066.x · Cited by 114
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease
Cohen, A. D., Landau, S. M., Snitz, B. E., Klunk, W. E., Blennow, K., & Zetterberg, H. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.004 · Cited by 106
Self-citationCorrelation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology
Smith, R., Wibom, M., Pawlik, D., Englund, E., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3692 · Cited by 111
Harada, R., Okamura, N., Furumoto, S., Tago, T., Maruyama, M., Higuchi, M., Yoshikawa, T., Arai, H., Iwata, R., Kudo, Y., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2261-2 · Cited by 108
“These findings are consistent with the findings from clinical PiB-PET studies showing no remarkable PiB retention in the medial temporal cortex of AD patients [7].”
BackgroundResultInfluentialAβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Devanand, D. P., Mikhno, A., Pelton, G. H., Cuasay, K., Pradhaban, G., Dileep Kumar, J. S., Upton, N., Lai, R., Gunn, R. N., Libri, V., et al. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710363715 · Cited by 107
“Regional (11)C-PIB binding correlates with amyloid plaques and vascular amyloid at autopsy.(7,8) In clinical studies, compared to healthy control individuals, patients with AD have higher (11)C-PIB binding in the prefrontal, precuneus, parietal, and cingulate regions, with the least binding differences in the medial t…”
Backgroundβ-Amyloid PET and neuropathology in dementia with Lewy bodies
Kantarci, K., Lowe, V. J., Chen, Q., Przybelski, S. A., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Jack, C. R., Graff‐Radford, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008818 · Cited by 118
“A subset of patients with LBD also have NPs with tau in the NP core, which are not readily distinguishable from DPs with Aβ PET and may lead to some inconsistencies in the determination of AD-related pathology in patients with pDLB.(5,6,17,18) Understanding the pathologic basis of Aβ PET findings in LBD is critical fo…”
BackgroundInfluentialUzuegbunam, B. C., Librizzi, D., & Yousefi, B. H. (2020) · Molecules · doi:10.3390/molecules25040977 · Cited by 115
“Additionally, it was confirmed that there is a direct corr lation of the retention of PiB in vivo with region-matched quantitative analyses of Aβ pl ques in the same patient, upon post-mortem examination f clinically diagnos and autopsy-confirmed D subjects [99].”
BackgroundMorimoto, K., Horio, J., Satoh, H., Sue, L., Beach, T., Arita, S., Tooyama, I., & Konishi, Y. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-101815 · Cited by 104
Grimmer, T., Tholen, S., Yousefi, B. H., Alexopoulos, P., Förschler, A., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Perneczky, R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.013 · Cited by 101
Self-citationDriscoll, I., Troncoso, J. C., Rudow, G., Sojkova, J., Pletnikova, O., Zhou, Y., Kraut, M. A., Ferrucci, L., Mathis, C. A., Klunk, W. E., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1025-1 · Cited by 104
Self-citationβ-Amyloid affects frontal and posterior brain networks in normal aging
Oh, H., Mormino, E. C., Madison, C., Hayenga, A., Smiljic, A., & Jagust, W. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.027 · Cited by 103
“Aβ deposition can now be measured in vivo with Pittsburgh Compound B (PIB) and positron emission tomography (PET) (Ikonomovic et al., 2008; Klunk et al., 2003, 2004).”
Influential
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.